From: Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas
MSC source | Cell surface marker | References |
---|---|---|
Bone marrow | Positive: SH2, SH3, CD29, CD44, CD71, CD73, CD124, CD90, CD105, CD106, CD120a Negative: CD34, CD45, CD19, CD3, HLA-DR, CD31, CD11b | |
Adipose tissue | Positive: CD13, CD29, CD44, CD73, HLA-I, CD90, CD105, CD166, HLA-ABC, Negative: CD10, CD14, CD24, CD31, HLA-DR, CD36, CD38, CD45, CD49d, CD117, CD133, CD34, CD106, HLAII, SSEA4 | |
Umbilical cord | Positive: CK8, CK18, CK19, CD10, CD13, HLA-I, CD29, CD73, CD105, CD106, CD90, CD44, CD73 Negative: CD14, CD31, CD33, CD34, HLA-DR, CD45, CD38, CD79, CD133, VWF | |
Human glioma | Positive: CD90, CD105, CD73, CD44, CD151, α-SMA, desmin, VE-cadherin, NG2, STRO-1, HLA-I Negative: CD31, CD34, CD133, CD45, HLA-DR, CD14, CD19, Nestin, SMM |